ID   TERT_HUMAN              Reviewed;        1132 AA.
AC   O14746; O14783; Q2XS35; Q8N6C3; Q8NG38; Q8NG46;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   18-JUN-2025, entry version 216.
DE   RecName: Full=Telomerase reverse transcriptase;
DE            EC=2.7.7.49 {ECO:0000269|PubMed:21602826, ECO:0000269|PubMed:29695869};
DE   AltName: Full=HEST2;
DE   AltName: Full=Telomerase catalytic subunit;
DE   AltName: Full=Telomerase-associated protein 2;
DE            Short=TP2;
GN   Name=TERT; Synonyms=EST2, TCS1, TRT;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9288757; DOI=10.1016/s0092-8674(00)80538-3;
RA   Meyerson M., Counter C.M., Eaton E.N., Ellisen L.W., Steiner P.,
RA   Caddle S.D., Ziaugra L., Beijersbergen R.L., Davidoff M.J., Liu Q.,
RA   Bacchetti S., Haber D.A., Weinberg R.A.;
RT   "hEST2, the putative human telomerase catalytic subunit gene, is up-
RT   regulated in tumor cells and during immortalization.";
RL   Cell 90:785-795(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Embryonic kidney;
RX   PubMed=9252327; DOI=10.1126/science.277.5328.955;
RA   Nakamura T.M., Morin G.B., Chapman K.B., Weinrich S.L., Andrews W.H.,
RA   Lingner J., Harley C.B., Cech T.R.;
RT   "Telomerase catalytic subunit homologs from fission yeast and human.";
RL   Science 277:955-959(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=10333526; DOI=10.1016/s0378-1119(99)00108-0;
RA   Wick M., Zubov D., Hagen G.;
RT   "Genomic organization and promoter characterization of the gene encoding
RT   the human telomerase reverse transcriptase (hTERT).";
RL   Gene 232:97-106(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=12869302; DOI=10.1016/s1476-5586(03)80051-9;
RA   Hisatomi H., Ohyashiki K., Ohyashiki J.H., Nagao K., Kanamaru T.,
RA   Hirata H., Hibi N., Tsukada Y.;
RT   "Expression profile of a gamma-deletion variant of the human telomerase
RT   reverse transcriptase gene.";
RL   Neoplasia 5:193-197(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3 AND 4).
RC   TISSUE=Stomach cancer;
RX   PubMed=14654914;
RA   Nagao K., Katsumata K., Aizawa Y., Saito N., Hirata H., Sasaki H.,
RA   Yamamoto S., Hikiji K., Koiwa T., Hisatomi H.;
RT   "Differential alternative splicing expressions of telomerase reverse
RT   transcriptase in gastrointestinal cell lines.";
RL   Oncol. Rep. 11:127-131(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Londono-Vallejo J.A.;
RT   "Sequence of a BAC carrying the entire hTERT gene.";
RL   Submitted (OCT-2001) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS TYR-412 AND THR-1062.
RG   NIEHS SNPs program;
RL   Submitted (OCT-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A.,
RA   Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R.,
RA   Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L.,
RA   Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N.,
RA   Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J.,
RA   Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A.,
RA   Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=8676067; DOI=10.1084/jem.183.6.2471;
RA   Weng N.P., Levine B.L., June C.H., Hodes R.J.;
RT   "Regulated expression of telomerase activity in human T lymphocyte
RT   development and activation.";
RL   J. Exp. Med. 183:2471-2479(1996).
RN   [11]
RP   FUNCTION IN TELOMERASE ACTIVITY, TISSUE SPECIFICITY, ASSOCIATION WITH TEP1,
RP   AND MUTAGENESIS OF ASP-712; ASP-868 AND ASP-869.
RX   PubMed=9389643; DOI=10.1101/gad.11.23.3109;
RA   Harrington L., Zhou W., McPhail T., Oulton R., Yeung D.S., Mar V.,
RA   Bass M.B., Robinson M.O.;
RT   "Human telomerase contains evolutionarily conserved catalytic and
RT   structural subunits.";
RL   Genes Dev. 11:3109-3115(1997).
RN   [12]
RP   RECONSTITUTION OF THE TELOMERASE COMPLEX, AND MUTAGENESIS OF ASP-712;
RP   ASP-868 AND ASP-869.
RX   PubMed=9443919; DOI=10.1016/s0960-9822(98)70067-3;
RA   Beattie T.L., Zhou W., Robinson M.O., Harrington L.;
RT   "Reconstitution of human telomerase activity in vitro.";
RL   Curr. Biol. 8:177-180(1998).
RN   [13]
RP   ASSOCIATION WITH TEP1.
RX   PubMed=11029039; DOI=10.1091/mbc.11.10.3329;
RA   Beattie T.L., Zhou W., Robinson M.O., Harrington L.;
RT   "Polymerization defects within human telomerase are distinct from
RT   telomerase RNA and TEP1 binding.";
RL   Mol. Biol. Cell 11:3329-3340(2000).
RN   [14]
RP   INTERACTION WITH HSPA1A; HSP90A AND PTGES3.
RX   PubMed=11274138; DOI=10.1074/jbc.c100055200;
RA   Forsythe H.L., Jarvis J.L., Turner J.W., Elmore L.W., Holt S.E.;
RT   "Stable association of hsp90 and p23, but Not hsp70, with active human
RT   telomerase.";
RL   J. Biol. Chem. 276:15571-15574(2001).
RN   [15]
RP   PHOSPHORYLATION AT TYR-707, SUBCELLULAR LOCATION, INTERACTION WITH RAN AND
RP   XP01, AND MUTAGENESIS OF TYR-707.
RX   PubMed=12808100; DOI=10.1128/mcb.23.13.4598-4610.2003;
RA   Haendeler J., Hoffmann J., Brandes R.P., Zeiher A.M., Dimmeler S.;
RT   "Hydrogen peroxide triggers nuclear export of telomerase reverse
RT   transcriptase via Src kinase family-dependent phosphorylation of tyrosine
RT   707.";
RL   Mol. Cell. Biol. 23:4598-4610(2003).
RN   [16]
RP   INTERACTION WITH MCRS1.
RX   PubMed=15044100; DOI=10.1016/j.bbrc.2004.02.166;
RA   Song H., Li Y., Chen G., Xing Z., Zhao J., Yokoyama K.K., Li T., Zhao M.;
RT   "Human MCRS2, a cell-cycle-dependent protein, associates with LPTS/PinX1
RT   and reduces the telomere length.";
RL   Biochem. Biophys. Res. Commun. 316:1116-1123(2004).
RN   [17]
RP   SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=14963003; DOI=10.1161/01.res.0000121104.05977.f3;
RA   Haendeler J., Hoffmann J., Diehl J.F., Vasa M., Spyridopoulos I.,
RA   Zeiher A.M., Dimmeler S.;
RT   "Antioxidants inhibit nuclear export of telomerase reverse transcriptase
RT   and delay replicative senescence of endothelial cells.";
RL   Circ. Res. 94:768-775(2004).
RN   [18]
RP   SUBCELLULAR LOCATION.
RX   PubMed=15138842; DOI=10.1007/s00418-004-0645-5;
RA   Yan P., Benhattar J., Seelentag W., Stehle J.C., Bosman F.T.;
RT   "Immunohistochemical localization of hTERT protein in human tissues.";
RL   Histochem. Cell Biol. 121:391-397(2004).
RN   [19]
RP   INTERACTION WITH NCL, AND SUBCELLULAR LOCATION.
RX   PubMed=15371412; DOI=10.1074/jbc.m407643200;
RA   Khurts S., Masutomi K., Delgermaa L., Arai K., Oishi N., Mizuno H.,
RA   Hayashi N., Hahn W.C., Murakami S.;
RT   "Nucleolin interacts with telomerase.";
RL   J. Biol. Chem. 279:51508-51515(2004).
RN   [20]
RP   FUNCTIONAL DOMAINS, AND MUTAGENESIS OF TRP-547 AND ASP-868.
RX   PubMed=15082768; DOI=10.1128/mcb.24.9.3720-3733.2004;
RA   Moriarty T.J., Marie-Egyptienne D.T., Autexier C.;
RT   "Functional organization of repeat addition processivity and DNA synthesis
RT   determinants in the human telomerase multimer.";
RL   Mol. Cell. Biol. 24:3720-3733(2004).
RN   [21]
RP   INTERACTION WITH MKRN1, AND UBIQUITINATION.
RX   PubMed=15805468; DOI=10.1101/gad.1289405;
RA   Kim J.H., Park S.-M., Kang M.R., Oh S.-Y., Lee T.H., Muller M.T.,
RA   Chung I.K.;
RT   "Ubiquitin ligase MKRN1 modulates telomere length homeostasis through a
RT   proteolysis of hTERT.";
RL   Genes Dev. 19:776-781(2005).
RN   [22]
RP   FUNCTION, AND MUTAGENESIS OF ASP-868.
RX   PubMed=15857955; DOI=10.1091/mbc.e05-02-0148;
RA   Moriarty T.J., Ward R.J., Taboski M.A., Autexier C.;
RT   "An anchor site-type defect in human telomerase that disrupts telomere
RT   length maintenance and cellular immortalization.";
RL   Mol. Biol. Cell 16:3152-3161(2005).
RN   [23]
RP   FUNCTION, AND MUTAGENESIS OF ARG-631; ASP-712 AND ASP-868.
RX   PubMed=17026956; DOI=10.1016/j.bbrc.2006.09.125;
RA   Rahman R., Mo L., Cui W.;
RT   "Telomerase with mutated catalytic motifs has dominant negative effects on
RT   telomerase activity and inhibits cell growth.";
RL   Biochem. Biophys. Res. Commun. 350:796-802(2006).
RN   [24]
RP   PHOSPHORYLATION, AND FUNCTION.
RX   PubMed=17548608; DOI=10.4049/jimmunol.178.12.7710;
RA   Plunkett F.J., Franzese O., Finney H.M., Fletcher J.M., Belaramani L.L.,
RA   Salmon M., Dokal I., Webster D., Lawson A.D., Akbar A.N.;
RT   "The loss of telomerase activity in highly differentiated CD8+CD28-CD27- T
RT   cells is associated with decreased Akt (Ser473) phosphorylation.";
RL   J. Immunol. 178:7710-7719(2007).
RN   [25]
RP   INTERACTION WITH NAT10.
RX   PubMed=18082603; DOI=10.1016/j.molcel.2007.09.023;
RA   Fu D., Collins K.;
RT   "Purification of human telomerase complexes identifies factors involved in
RT   telomerase biogenesis and telomere length regulation.";
RL   Mol. Cell 28:773-785(2007).
RN   [26]
RP   FUNCTION, DNA-BINDING, AND MUTAGENESIS OF 137-TRP--LEU-141; ASP-712 AND
RP   930-TRP--LEU-934.
RX   PubMed=17296728; DOI=10.1128/mcb.02368-06;
RA   Wyatt H.D., Lobb D.A., Beattie T.L.;
RT   "Characterization of physical and functional anchor site interactions in
RT   human telomerase.";
RL   Mol. Cell. Biol. 27:3226-3240(2007).
RN   [27]
RP   FUNCTION, AND MUTAGENESIS OF LEU-866 AND VAL-867.
RX   PubMed=17264120; DOI=10.1093/nar/gkm002;
RA   Drosopoulos W.C., Prasad V.R.;
RT   "The active site residue Valine 867 in human telomerase reverse
RT   transcriptase influences nucleotide incorporation and fidelity.";
RL   Nucleic Acids Res. 35:1155-1168(2007).
RN   [28]
RP   INTERACTION WITH PTPN11, PHOSPHORYLATION AT TYR-707, SUBCELLULAR LOCATION,
RP   AND MUTAGENESIS OF TYR-707.
RX   PubMed=18829466; DOI=10.1074/jbc.m805138200;
RA   Jakob S., Schroeder P., Lukosz M., Buchner N., Spyridopoulos I.,
RA   Altschmied J., Haendeler J.;
RT   "Nuclear protein tyrosine phosphatase Shp-2 is one important negative
RT   regulator of nuclear export of telomerase reverse transcriptase.";
RL   J. Biol. Chem. 283:33155-33161(2008).
RN   [29]
RP   PHOSPHORYLATION, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=19188162; DOI=10.1158/1078-0432.ccr-08-0792;
RA   Ram R., Uziel O., Eldan O., Fenig E., Beery E., Lichtenberg S.,
RA   Nordenberg Y., Lahav M.;
RT   "Ionizing radiation up-regulates telomerase activity in cancer cell lines
RT   by post-translational mechanism via ras/phosphatidylinositol 3-kinase/Akt
RT   pathway.";
RL   Clin. Cancer Res. 15:914-923(2009).
RN   [30]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PML.
RX   PubMed=19567472; DOI=10.1242/jcs.048066;
RA   Oh W., Ghim J., Lee E.W., Yang M.R., Kim E.T., Ahn J.H., Song J.;
RT   "PML-IV functions as a negative regulator of telomerase by interacting with
RT   TERT.";
RL   J. Cell Sci. 122:2613-2622(2009).
RN   [31]
RP   INTERACTION WITH SMARCA4, AND FUNCTION.
RX   PubMed=19571879; DOI=10.1038/nature08137;
RA   Park J.I., Venteicher A.S., Hong J.Y., Choi J., Jun S., Shkreli M.,
RA   Chang W., Meng Z., Cheung P., Ji H., McLaughlin M., Veenstra T.D.,
RA   Nusse R., McCrea P.D., Artandi S.E.;
RT   "Telomerase modulates Wnt signalling by association with target gene
RT   chromatin.";
RL   Nature 460:66-72(2009).
RN   [32]
RP   FUNCTION, DNA-BINDING, AND MUTAGENESIS OF GLN-169.
RX   PubMed=19777057; DOI=10.1371/journal.pone.0007176;
RA   Wyatt H.D., Tsang A.R., Lobb D.A., Beattie T.L.;
RT   "Human telomerase reverse transcriptase (hTERT) Q169 is essential for
RT   telomerase function in vitro and in vivo.";
RL   PLoS ONE 4:E7176-E7176(2009).
RN   [33]
RP   IDENTIFICATION IN THE TELOMERASE HOLOENZYME COMPLEX.
RX   PubMed=19179534; DOI=10.1126/science.1165357;
RA   Venteicher A.S., Abreu E.B., Meng Z., McCann K.E., Terns R.M.,
RA   Veenstra T.D., Terns M.P., Artandi S.E.;
RT   "A human telomerase holoenzyme protein required for Cajal body localization
RT   and telomere synthesis.";
RL   Science 323:644-648(2009).
RN   [34]
RP   IDENTIFICATION IN THE TELOMERASE HOLOENZYME COMPLEX.
RX   PubMed=20351177; DOI=10.1128/mcb.00151-10;
RA   Egan E.D., Collins K.;
RT   "Specificity and stoichiometry of subunit interactions in the human
RT   telomerase holoenzyme assembled in vivo.";
RL   Mol. Cell. Biol. 30:2775-2786(2010).
RN   [35]
RP   INTERACTION WITH DHX36.
RX   PubMed=21846770; DOI=10.1093/nar/gkr630;
RA   Lattmann S., Stadler M.B., Vaughn J.P., Akman S.A., Nagamine Y.;
RT   "The DEAH-box RNA helicase RHAU binds an intramolecular RNA G-quadruplex in
RT   TERC and associates with telomerase holoenzyme.";
RL   Nucleic Acids Res. 39:9390-9404(2011).
RN   [36]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH NVL.
RX   PubMed=22226966; DOI=10.1016/j.bbrc.2011.12.101;
RA   Her J., Chung I.K.;
RT   "The AAA-ATPase NVL2 is a telomerase component essential for holoenzyme
RT   assembly.";
RL   Biochem. Biophys. Res. Commun. 417:1086-1092(2012).
RN   [37]
RP   PHOSPHORYLATION AT SER-227, SUBCELLULAR LOCATION, AND NUCLEAR LOCALIZATION
RP   SIGNAL.
RX   PubMed=22366458; DOI=10.1242/jcs.099267;
RA   Chung J., Khadka P., Chung I.K.;
RT   "Nuclear import of hTERT requires a bipartite nuclear localization signal
RT   and Akt-mediated phosphorylation.";
RL   J. Cell Sci. 125:2684-2697(2012).
RN   [38]
RP   PHOSPHORYLATION AT SER-457, UBIQUITINATION, AND MUTAGENESIS OF SER-457.
RX   PubMed=23362280; DOI=10.1074/jbc.m112.416792;
RA   Jung H.Y., Wang X., Jun S., Park J.I.;
RT   "Dyrk2-associated EDD-DDB1-VprBP E3 ligase inhibits telomerase by TERT
RT   degradation.";
RL   J. Biol. Chem. 288:7252-7262(2013).
RN   [39]
RP   UBIQUITINATION.
RX   PubMed=23612978; DOI=10.1074/jbc.m112.416735;
RA   Wang X., Singh S., Jung H.Y., Yang G., Jun S., Sastry K.J., Park J.I.;
RT   "HIV-1 Vpr protein inhibits telomerase activity via the EDD-DDB1-VPRBP E3
RT   ligase complex.";
RL   J. Biol. Chem. 288:15474-15480(2013).
RN   [40]
RP   INVOLVEMENT IN CMM9.
RX   PubMed=23348503; DOI=10.1126/science.1230062;
RA   Horn S., Figl A., Rachakonda P.S., Fischer C., Sucker A., Gast A.,
RA   Kadel S., Moll I., Nagore E., Hemminki K., Schadendorf D., Kumar R.;
RT   "TERT promoter mutations in familial and sporadic melanoma.";
RL   Science 339:959-961(2013).
RN   [41]
RP   INTERACTION WITH ATF7.
RX   PubMed=29490055; DOI=10.1093/nar/gky155;
RA   Maekawa T., Liu B., Nakai D., Yoshida K., Nakamura K.I., Yasukawa M.,
RA   Koike M., Takubo K., Chatton B., Ishikawa F., Masutomi K., Ishii S.;
RT   "ATF7 mediates TNF-alpha-induced telomere shortening.";
RL   Nucleic Acids Res. 46:4487-4504(2018).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 461-469 IN COMPLEX WITH CLASS I
RP   MAJOR HISTOCOMPATIBILITY COMPLEX (MHC).
RX   PubMed=16323248; DOI=10.1002/eji.200535424;
RA   Cole D.K., Rizkallah P.J., Gao F., Watson N.I., Boulter J.M., Bell J.I.,
RA   Sami M., Gao G.F., Jakobsen B.K.;
RT   "Crystal structure of HLA-A*2402 complexed with a telomerase peptide.";
RL   Eur. J. Immunol. 36:170-179(2006).
RN   [43]
RP   STRUCTURE BY ELECTRON MICROSCOPY (7.7 ANGSTROMS) OF THE TELOMERASE
RP   HOLOENZYME COMPLEX, AND CATALYTIC ACTIVITY.
RX   PubMed=29695869; DOI=10.1038/s41586-018-0062-x;
RA   Nguyen T.H.D., Tam J., Wu R.A., Greber B.J., Toso D., Nogales E.,
RA   Collins K.;
RT   "Cryo-EM structure of substrate-bound human telomerase holoenzyme.";
RL   Nature 557:190-195(2018).
RN   [44]
RP   VARIANT AA THR-202, VARIANTS DKCA2 TRP-979 AND LEU-1127, CHARACTERIZATION
RP   OF VARIANT AA THR-202, AND CHARACTERIZATION OF VARIANTS DKCA2 TRP-979 AND
RP   LEU-1127.
RX   PubMed=15885610; DOI=10.1016/j.bcmd.2004.12.008;
RA   Vulliamy T.J., Walne A., Baskaradas A., Mason P.J., Marrone A., Dokal I.;
RT   "Mutations in the reverse transcriptase component of telomerase (TERT) in
RT   patients with bone marrow failure.";
RL   Blood Cells Mol. Dis. 34:257-263(2005).
RN   [45]
RP   VARIANTS PFBMFT1 THR-202; TYR-412; MET-694; CYS-772 AND MET-1090, AND
RP   VARIANTS THR-279; GLU-441 DEL AND THR-1062.
RX   PubMed=15814878; DOI=10.1056/nejmoa042980;
RA   Yamaguchi H., Calado R.T., Ly H., Kajigaya S., Baerlocher G.M.,
RA   Chanock S.J., Lansdorp P.M., Young N.S.;
RT   "Mutations in TERT, the gene for telomerase reverse transcriptase, in
RT   aplastic anemia.";
RL   N. Engl. J. Med. 352:1413-1424(2005).
RN   [46]
RP   VARIANT DKCA2 ASN-902, AND CHARACTERIZATION OF VARIANT DKCA2 ASN-902.
RX   PubMed=16247010; DOI=10.1073/pnas.0508124102;
RA   Armanios M., Chen J.-L., Chang Y.-P.C., Brodsky R.A., Hawkins A.,
RA   Griffin C.A., Eshleman J.R., Cohen A.R., Chakravarti A., Hamosh A.,
RA   Greider C.W.;
RT   "Haploinsufficiency of telomerase reverse transcriptase leads to
RT   anticipation in autosomal dominant dyskeratosis congenita.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:15960-15964(2005).
RN   [47]
RP   INVOLVEMENT IN CAD SUSCEPTIBILITY.
RX   PubMed=16890917; DOI=10.1016/j.bbrc.2006.07.103;
RA   Matsubara Y., Murata M., Watanabe K., Saito I., Miyaki K., Omae K.,
RA   Ishikawa M., Matsushita K., Iwanaga S., Ogawa S., Ikeda Y.;
RT   "Coronary artery disease and a functional polymorphism of hTERT.";
RL   Biochem. Biophys. Res. Commun. 348:669-672(2006).
RN   [48]
RP   VARIANT DKCB4 ARG-721.
RX   PubMed=16332973; DOI=10.1182/blood-2005-07-2622;
RA   Vulliamy T.J., Marrone A., Knight S.W., Walne A., Mason P.J., Dokal I.;
RT   "Mutations in dyskeratosis congenita: their impact on telomere length and
RT   the diversity of clinical presentation.";
RL   Blood 107:2680-2685(2006).
RN   [49]
RP   VARIANTS AA ASP-682 AND MET-726, AND CHARACTERIZATION OF VARIANT AA
RP   MET-726.
RX   PubMed=16627250;
RA   Liang J., Yagasaki H., Kamachi Y., Hama A., Matsumoto K., Kato K., Kudo K.,
RA   Kojima S.;
RT   "Mutations in telomerase catalytic protein in Japanese children with
RT   aplastic anemia.";
RL   Haematologica 91:656-658(2006).
RN   [50]
RP   VARIANT AA ASN-570, AND CHARACTERIZATION OF VARIANTS ASN-570; ASP-682;
RP   ARG-721; MET-726; ASN-902; TRP-979 AND LEU-1127.
RX   PubMed=16990594; DOI=10.1182/blood-2006-07-035089;
RA   Xin Z.T., Beauchamp A.D., Calado R.T., Bradford J.W., Regal J.A.,
RA   Shenoy A., Liang Y., Lansdorp P.M., Young N.S., Ly H.;
RT   "Functional characterization of natural telomerase mutations found in
RT   patients with hematologic disorders.";
RL   Blood 109:524-532(2007).
RN   [51]
RP   VARIANTS DKCB4 CYS-811 AND TRP-901, AND CHARACTERIZATION OF VARIANTS DKCB4
RP   CYS-811 AND TRP-901.
RX   PubMed=17785587; DOI=10.1182/blood-2006-12-062851;
RA   Marrone A., Walne A., Tamary H., Masunari Y., Kirwan M., Beswick R.,
RA   Vulliamy T., Dokal I.;
RT   "Telomerase reverse-transcriptase homozygous mutations in autosomal
RT   recessive dyskeratosis congenita and Hoyeraal-Hreidarsson syndrome.";
RL   Blood 110:4198-4205(2007).
RN   [52]
RP   VARIANTS PFBMFT1 GLN-55 AND MET-1110, AND CHARACTERIZATION OF VARIANTS
RP   PFBMFT1 GLN-55 AND MET-1110.
RX   PubMed=17392301; DOI=10.1056/nejmoa066157;
RA   Armanios M.Y., Chen J.J., Cogan J.D., Alder J.K., Ingersoll R.G.,
RA   Markin C., Lawson W.E., Xie M., Vulto I., Phillips J.A., Lansdorp P.M.,
RA   Greider C.W., Loyd J.E.;
RT   "Telomerase mutations in families with idiopathic pulmonary fibrosis.";
RL   N. Engl. J. Med. 356:1317-1326(2007).
RN   [53]
RP   VARIANT PFBMFT1 HIS-865.
RX   PubMed=17460043; DOI=10.1073/pnas.0701009104;
RA   Tsakiri K.D., Cronkhite J.T., Kuan P.J., Xing C., Raghu G., Weissler J.C.,
RA   Rosenblatt R.L., Shay J.W., Garcia C.K.;
RT   "Adult-onset pulmonary fibrosis caused by mutations in telomerase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:7552-7557(2007).
RN   [54]
RP   VARIANTS DKCB4 TYR-412 AND SER-704, AND CHARACTERIZATION OF VARIANTS DKCB4
RP   TYR-412 AND SER-704.
RX   PubMed=18042801; DOI=10.1182/blood-2007-10-120907;
RA   Du H.Y., Pumbo E., Manley P., Field J.J., Bayliss S.J., Wilson D.B.,
RA   Mason P.J., Bessler M.;
RT   "Complex inheritance pattern of dyskeratosis congenita in two families with
RT   2 different mutations in the telomerase reverse transcriptase gene.";
RL   Blood 111:1128-1130(2008).
RN   [55]
RP   VARIANTS ALA-65; MET-299; LYS-522 AND THR-1062, AND VARIANTS AA THR-202;
RP   TYR-412; GLU-441 DEL; ASN-570; GLN-631; MET-694 AND LEU-785.
RX   PubMed=19760749; DOI=10.1002/humu.21115;
RA   Kirwan M., Vulliamy T., Marrone A., Walne A.J., Beswick R., Hillmen P.,
RA   Kelly R., Stewart A., Bowen D., Schonland S.O., Whittle A.M., McVerry A.,
RA   Gilleece M., Dokal I.;
RT   "Defining the pathogenic role of telomerase mutations in myelodysplastic
RT   syndrome and acute myeloid leukemia.";
RL   Hum. Mutat. 30:1567-1573(2009).
RN   [56]
RP   VARIANTS ALA-65; MET-299; TYR-412; GLU-441 DEL; LYS-522 AND THR-1062.
RX   PubMed=19147845; DOI=10.1073/pnas.0807057106;
RA   Calado R.T., Regal J.A., Hills M., Yewdell W.T., Dalmazzo L.F., Zago M.A.,
RA   Lansdorp P.M., Hogge D., Chanock S.J., Estey E.H., Falcao R.P., Young N.S.;
RT   "Constitutional hypomorphic telomerase mutations in patients with acute
RT   myeloid leukemia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:1187-1192(2009).
RN   [57]
RP   VARIANTS PFBMFT1 MET-170; THR-716; PHE-841; ARG-902 AND PHE-1025, AND
RP   CHARACTERIZATION OF VARIANTS PFBMFT1 MET-170; THR-716; PHE-841 AND
RP   PHE-1025.
RX   PubMed=21436073; DOI=10.1182/blood-2010-11-322149;
RA   Parry E.M., Alder J.K., Qi X., Chen J.J., Armanios M.;
RT   "Syndrome complex of bone marrow failure and pulmonary fibrosis predicts
RT   germline defects in telomerase.";
RL   Blood 117:5607-5611(2011).
RN   [58]
RP   VARIANT DKCB4 SER-704, VARIANT DKCA2 TRP-979, CHARACTERIZATION OF VARIANT
RP   DKCB4 SER-704, CHARACTERIZATION OF VARIANT DKCA2 TRP-979, AND CATALYTIC
RP   ACTIVITY.
RX   PubMed=21602826; DOI=10.1038/nature10084;
RA   Batista L.F., Pech M.F., Zhong F.L., Nguyen H.N., Xie K.T., Zaug A.J.,
RA   Crary S.M., Choi J., Sebastiano V., Cherry A., Giri N., Wernig M.,
RA   Alter B.P., Cech T.R., Savage S.A., Reijo Pera R.A., Artandi S.E.;
RT   "Telomere shortening and loss of self-renewal in dyskeratosis congenita
RT   induced pluripotent stem cells.";
RL   Nature 474:399-402(2011).
RN   [59]
RP   VARIANTS PFBMFT1 ILE-791 AND MET-867, AND CHARACTERIZATION OF VARIANTS
RP   PFBMFT1 ILE-791 AND MET-867.
RX   PubMed=21483807; DOI=10.1371/journal.pgen.1001352;
RA   Alder J.K., Cogan J.D., Brown A.F., Anderson C.J., Lawson W.E.,
RA   Lansdorp P.M., Phillips J.A. III, Loyd J.E., Chen J.J., Armanios M.;
RT   "Ancestral mutation in telomerase causes defects in repeat addition
RT   processivity and manifests as familial pulmonary fibrosis.";
RL   PLoS Genet. 7:E1001352-E1001352(2011).
RN   [60]
RP   VARIANT PFBMFT1 LEU-923.
RX   PubMed=22512499; DOI=10.1056/nejmc1200999;
RA   Gansner J.M., Rosas I.O., Ebert B.L.;
RT   "Pulmonary fibrosis, bone marrow failure, and telomerase mutation.";
RL   N. Engl. J. Med. 366:1551-1553(2012).
RN   [61]
RP   VARIANTS PRO-381 AND THR-1062.
RX   PubMed=31355908; DOI=10.1111/cge.13614;
RA   Krenke K., Szczaluba K., Bielecka T., Rydzanicz M., Lange J., Koppolu A.,
RA   Ploski R.;
RT   "FARSA mutations mimic phenylalanyl-tRNA synthetase deficiency caused by
RT   FARSB defects.";
RL   Clin. Genet. 96:468-472(2019).
CC   -!- FUNCTION: Telomerase is a ribonucleoprotein enzyme essential for the
CC       replication of chromosome termini in most eukaryotes. Active in
CC       progenitor and cancer cells. Inactive, or very low activity, in normal
CC       somatic cells. Catalytic component of the teleromerase holoenzyme
CC       complex whose main activity is the elongation of telomeres by acting as
CC       a reverse transcriptase that adds simple sequence repeats to chromosome
CC       ends by copying a template sequence within the RNA component of the
CC       enzyme. Catalyzes the RNA-dependent extension of 3'-chromosomal termini
CC       with the 6-nucleotide telomeric repeat unit, 5'-TTAGGG-3'. The
CC       catalytic cycle involves primer binding, primer extension and release
CC       of product once the template boundary has been reached or nascent
CC       product translocation followed by further extension. More active on
CC       substrates containing 2 or 3 telomeric repeats. Telomerase activity is
CC       regulated by a number of factors including telomerase complex-
CC       associated proteins, chaperones and polypeptide modifiers. Modulates
CC       Wnt signaling. Plays important roles in aging and antiapoptosis.
CC       {ECO:0000269|PubMed:14963003, ECO:0000269|PubMed:15082768,
CC       ECO:0000269|PubMed:15857955, ECO:0000269|PubMed:17026956,
CC       ECO:0000269|PubMed:17264120, ECO:0000269|PubMed:17296728,
CC       ECO:0000269|PubMed:17548608, ECO:0000269|PubMed:19188162,
CC       ECO:0000269|PubMed:19567472, ECO:0000269|PubMed:19571879,
CC       ECO:0000269|PubMed:19777057, ECO:0000269|PubMed:9389643}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=DNA(n) + a 2'-deoxyribonucleoside 5'-triphosphate = DNA(n+1) +
CC         diphosphate; Xref=Rhea:RHEA:22508, Rhea:RHEA-COMP:17339, Rhea:RHEA-
CC         COMP:17340, ChEBI:CHEBI:33019, ChEBI:CHEBI:61560, ChEBI:CHEBI:173112;
CC         EC=2.7.7.49; Evidence={ECO:0000269|PubMed:21602826,
CC         ECO:0000269|PubMed:29695869};
CC   -!- SUBUNIT: Catalytic component of the telomerase holoenzyme complex
CC       composed of one molecule of TERT, one molecule of WRAP53/TCAB1, two
CC       molecules of H/ACA ribonucleoprotein complex subunits DKC1, NOP10, NHP2
CC       and GAR1, and a telomerase RNA template component (TERC)
CC       (PubMed:19179534, PubMed:20351177, PubMed:29695869). The telomerase
CC       holoenzyme complex is associated with TEP1, SMG6/EST1A and POT1
CC       (PubMed:19179534). The molecular chaperone HSP90/P23 complex is
CC       required for correct assembly and stabilization of the active
CC       telomerase (PubMed:11274138). Interacts directly with HSP90A and PTGES3
CC       (PubMed:11274138). Interacts with HSPA1A; the interaction occurs in the
CC       absence of TERC and dissociates once the complex has formed
CC       (PubMed:11274138). Interacts with RAN; the interaction promotes nuclear
CC       export of TERT (PubMed:12808100). Interacts with XPO1
CC       (PubMed:12808100). Interacts with PTPN11; the interaction retains TERT
CC       in the nucleus (PubMed:18829466). Interacts with NCL (via RRM1 and C-
CC       terminal RRM4/Arg/Gly-rich domains); the interaction is important for
CC       nucleolar localization of TERT (PubMed:15371412). Interacts with
CC       SMARCA4 (via the bromodomain); the interaction regulates Wnt-mediated
CC       signaling (By similarity). Interacts with MCRS1 (isoform MCRS2); the
CC       interaction inhibits in vitro telomerase activity (PubMed:15044100).
CC       Interacts with PIF1; the interaction has no effect on the elongation
CC       activity of TERT (By similarity). Interacts with PML; the interaction
CC       recruits TERT to PML bodies and inhibits telomerase activity
CC       (PubMed:19567472). Interacts with GNL3L (By similarity). Interacts with
CC       isoform 1 and isoform 2 of NVL (PubMed:22226966). Interacts with DHX36
CC       (PubMed:21846770). Interacts with ATF7 (PubMed:29490055).
CC       {ECO:0000250|UniProtKB:O70372, ECO:0000269|PubMed:11274138,
CC       ECO:0000269|PubMed:12808100, ECO:0000269|PubMed:15044100,
CC       ECO:0000269|PubMed:15371412, ECO:0000269|PubMed:18829466,
CC       ECO:0000269|PubMed:19179534, ECO:0000269|PubMed:19567472,
CC       ECO:0000269|PubMed:20351177, ECO:0000269|PubMed:21846770,
CC       ECO:0000269|PubMed:22226966, ECO:0000269|PubMed:29490055,
CC       ECO:0000269|PubMed:29695869}.
CC   -!- INTERACTION:
CC       O14746; P35222: CTNNB1; NbExp=2; IntAct=EBI-1772203, EBI-491549;
CC       O14746; Q9BVP2: GNL3; NbExp=3; IntAct=EBI-1772203, EBI-641642;
CC       O14746; P06748: NPM1; NbExp=5; IntAct=EBI-1772203, EBI-78579;
CC       O14746; Q96BK5: PINX1; NbExp=6; IntAct=EBI-1772203, EBI-721782;
CC       O14746; P29590-5: PML; NbExp=7; IntAct=EBI-1772203, EBI-304008;
CC       O14746; Q9Y265: RUVBL1; NbExp=11; IntAct=EBI-1772203, EBI-353675;
CC       O14746; P51532: SMARCA4; NbExp=8; IntAct=EBI-1772203, EBI-302489;
CC       O14746; O14746: TERT; NbExp=3; IntAct=EBI-1772203, EBI-1772203;
CC       O14746; O14773-1: TPP1; NbExp=2; IntAct=EBI-1772203, EBI-15619703;
CC       O14746; Q92900: UPF1; NbExp=3; IntAct=EBI-1772203, EBI-373471;
CC       O14746; P03126: E6; Xeno; NbExp=7; IntAct=EBI-1772203, EBI-1177242;
CC   -!- SUBCELLULAR LOCATION: Nucleus, nucleolus {ECO:0000269|PubMed:22226966}.
CC       Nucleus, nucleoplasm. Nucleus. Chromosome, telomere. Cytoplasm.
CC       Nucleus, PML body. Note=Shuttling between nuclear and cytoplasm depends
CC       on cell cycle, phosphorylation states, transformation and DNA damage.
CC       Diffuse localization in the nucleoplasm. Enriched in nucleoli of
CC       certain cell types. Translocated to the cytoplasm via nuclear pores in
CC       a CRM1/RAN-dependent manner involving oxidative stress-mediated
CC       phosphorylation at Tyr-707. Dephosphorylation at this site by SHP2
CC       retains TERT in the nucleus. Translocated to the nucleus by
CC       phosphorylation by AKT.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=O14746-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O14746-2; Sequence=VSP_019587, VSP_019588;
CC       Name=3;
CC         IsoId=O14746-3; Sequence=VSP_021727;
CC       Name=4;
CC         IsoId=O14746-4; Sequence=VSP_053369, VSP_019587, VSP_019588;
CC   -!- TISSUE SPECIFICITY: Expressed at a high level in thymocyte
CC       subpopulations, at an intermediate level in tonsil T-lymphocytes, and
CC       at a low to undetectable level in peripheral blood T-lymphocytes.
CC       {ECO:0000269|PubMed:8676067, ECO:0000269|PubMed:9389643}.
CC   -!- INDUCTION: Activated by cytotoxic events and down-regulated during
CC       aging. In peripheral T-lymphocytes, induced By CD3 and by
CC       PMA/ionomycin. Inhibited by herbimycin B. {ECO:0000269|PubMed:8676067}.
CC   -!- DOMAIN: The primer grip sequence in the RT domain is required for
CC       telomerase activity and for stable association with short telomeric
CC       primers.
CC   -!- DOMAIN: The RNA-interacting domain 1 (RD1)/N-terminal extension (NTE)
CC       is required for interaction with the pseudoknot-template domain of each
CC       of TERC dimers. It contains anchor sites that bind primer nucleotides
CC       upstream of the RNA-DNA hybrid and is thus an essential determinant of
CC       repeat addition processivity.
CC   -!- DOMAIN: The RNA-interacting domain 2 (RD2) is essential for both
CC       interaction with the CR4-CR5 domain of TERC and for DNA synthesis.
CC   -!- PTM: Phosphorylation at Tyr-707 under oxidative stress leads to
CC       translocation of TERT to the cytoplasm and reduces its antiapoptotic
CC       activity. Dephosphorylated by SHP2/PTPN11 leading to nuclear retention.
CC       Phosphorylation at Ser-227 by the AKT pathway promotes nuclear
CC       location. Phosphorylation at the G2/M phase at Ser-457 by DYRK2
CC       promotes ubiquitination by the EDVP complex and degradation.
CC       {ECO:0000269|PubMed:12808100, ECO:0000269|PubMed:18829466,
CC       ECO:0000269|PubMed:22366458, ECO:0000269|PubMed:23362280}.
CC   -!- PTM: Ubiquitinated by the EDVP complex, a E3 ligase complex following
CC       phosphorylation at Ser-457 by DYRK2. Ubiquitinated leads to proteasomal
CC       degradation. {ECO:0000269|PubMed:23362280}.
CC   -!- PTM: (Microbial infection) In case of infection by HIV-1, the EDVP
CC       complex is hijacked by HIV-1 via interaction between HIV-1 Vpr and
CC       DCAF1/VPRBP, leading to ubiquitination and degradation.
CC       {ECO:0000269|PubMed:23362280}.
CC   -!- DISEASE: Note=Activation of telomerase has been implicated in cell
CC       immortalization and cancer cell pathogenesis.
CC   -!- DISEASE: Aplastic anemia (AA) [MIM:609135]: A form of anemia in which
CC       the bone marrow fails to produce adequate numbers of peripheral blood
CC       elements. It is characterized by peripheral pancytopenia and marrow
CC       hypoplasia. {ECO:0000269|PubMed:15885610, ECO:0000269|PubMed:16627250,
CC       ECO:0000269|PubMed:16990594, ECO:0000269|PubMed:19760749}. Note=Disease
CC       susceptibility is associated with variants affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Note=Genetic variations in TERT are associated with coronary
CC       artery disease (CAD).
CC   -!- DISEASE: Dyskeratosis congenita, autosomal dominant, 2 (DKCA2)
CC       [MIM:613989]: A rare multisystem disorder caused by defective telomere
CC       maintenance. It is characterized by progressive bone marrow failure,
CC       and the clinical triad of reticulated skin hyperpigmentation, nail
CC       dystrophy, and mucosal leukoplakia. Common but variable features
CC       include premature graying, aplastic anemia, low platelets,
CC       osteoporosis, pulmonary fibrosis, and liver fibrosis among others.
CC       Early mortality is often associated with bone marrow failure,
CC       infections, fatal pulmonary complications, or malignancy.
CC       {ECO:0000269|PubMed:15885610, ECO:0000269|PubMed:16247010,
CC       ECO:0000269|PubMed:21602826}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Pulmonary fibrosis, and/or bone marrow failure syndrome,
CC       telomere-related, 1 (PFBMFT1) [MIM:614742]: An autosomal dominant
CC       disease associated with shortened telomeres. Pulmonary fibrosis is the
CC       most common manifestation. Other manifestations include aplastic anemia
CC       due to bone marrow failure, hepatic fibrosis, and increased cancer
CC       risk, particularly myelodysplastic syndrome and acute myeloid leukemia.
CC       Phenotype, age at onset, and severity are determined by telomere
CC       length. {ECO:0000269|PubMed:15814878, ECO:0000269|PubMed:17392301,
CC       ECO:0000269|PubMed:17460043, ECO:0000269|PubMed:21436073,
CC       ECO:0000269|PubMed:21483807, ECO:0000269|PubMed:22512499}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Dyskeratosis congenita, autosomal recessive, 4 (DKCB4)
CC       [MIM:613989]: A severe form of dyskeratosis congenita, a rare
CC       multisystem disorder caused by defective telomere maintenance. It is
CC       characterized by progressive bone marrow failure, and the clinical
CC       triad of reticulated skin hyperpigmentation, nail dystrophy, and
CC       mucosal leukoplakia. Common but variable features include premature
CC       graying, aplastic anemia, low platelets, osteoporosis, pulmonary
CC       fibrosis, and liver fibrosis among others. Early mortality is often
CC       associated with bone marrow failure, infections, fatal pulmonary
CC       complications, or malignancy. {ECO:0000269|PubMed:16332973,
CC       ECO:0000269|PubMed:17785587, ECO:0000269|PubMed:18042801,
CC       ECO:0000269|PubMed:21602826}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Melanoma, cutaneous malignant 9 (CMM9) [MIM:615134]: A
CC       malignant neoplasm of melanocytes, arising de novo or from a pre-
CC       existing benign nevus, which occurs most often in the skin but may also
CC       involve other sites. {ECO:0000269|PubMed:23348503}. Note=Disease
CC       susceptibility is associated with variants affecting the gene
CC       represented in this entry.
CC   -!- MISCELLANEOUS: [Isoform 3]: May be produced at very low levels due to a
CC       premature stop codon in the mRNA, leading to nonsense-mediated mRNA
CC       decay. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the reverse transcriptase family. Telomerase
CC       subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF018167; AAC51724.1; -; mRNA.
DR   EMBL; AF015950; AAC51672.1; -; mRNA.
DR   EMBL; AF128894; AAD30037.1; -; Genomic_DNA.
DR   EMBL; AF128893; AAD30037.1; JOINED; Genomic_DNA.
DR   EMBL; AB085628; BAC11010.1; -; mRNA.
DR   EMBL; AB086379; BAC11014.1; -; mRNA.
DR   EMBL; AB086950; BAC11015.1; -; mRNA.
DR   EMBL; AY007685; AAG23289.1; -; Genomic_DNA.
DR   EMBL; DQ264729; ABB72674.1; -; Genomic_DNA.
DR   EMBL; AC114291; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471102; EAX08167.1; -; Genomic_DNA.
DR   CCDS; CCDS3861.2; -. [O14746-1]
DR   CCDS; CCDS54831.1; -. [O14746-3]
DR   PIR; T03844; T03844.
DR   RefSeq; NP_001180305.1; NM_001193376.3. [O14746-3]
DR   RefSeq; NP_937983.2; NM_198253.3. [O14746-1]
DR   PDB; 2BCK; X-ray; 2.80 A; C/F=461-469.
DR   PDB; 4B18; X-ray; 2.52 A; B=222-240.
DR   PDB; 4MNQ; X-ray; 2.74 A; C=540-548.
DR   PDB; 5MEN; X-ray; 2.81 A; C=540-548.
DR   PDB; 5MEO; X-ray; 1.77 A; C=540-548.
DR   PDB; 5MEP; X-ray; 2.71 A; C/F=540-548.
DR   PDB; 5MEQ; X-ray; 2.27 A; C=540-546.
DR   PDB; 5MER; X-ray; 1.88 A; C/F=540-546.
DR   PDB; 5UGW; X-ray; 2.31 A; A=961-1132.
DR   PDB; 7BG9; EM; 3.80 A; A=1-1132.
DR   PDB; 7QXA; EM; 3.20 A; A=1-1132.
DR   PDB; 7QXB; EM; 3.91 A; A=1-1132.
DR   PDB; 7QXS; EM; 3.91 A; A=1-1132.
DR   PDB; 7TRD; EM; 3.30 A; A=1-1132.
DR   PDB; 7TRE; EM; 3.50 A; A=1-1132.
DR   PDB; 7TRF; EM; 3.70 A; A=1-1132.
DR   PDB; 7V99; EM; 3.54 A; A=1-1132.
DR   PDBsum; 2BCK; -.
DR   PDBsum; 4B18; -.
DR   PDBsum; 4MNQ; -.
DR   PDBsum; 5MEN; -.
DR   PDBsum; 5MEO; -.
DR   PDBsum; 5MEP; -.
DR   PDBsum; 5MEQ; -.
DR   PDBsum; 5MER; -.
DR   PDBsum; 5UGW; -.
DR   PDBsum; 7BG9; -.
DR   PDBsum; 7QXA; -.
DR   PDBsum; 7QXB; -.
DR   PDBsum; 7QXS; -.
DR   PDBsum; 7TRD; -.
DR   PDBsum; 7TRE; -.
DR   PDBsum; 7TRF; -.
DR   PDBsum; 7V99; -.
DR   AlphaFoldDB; O14746; -.
DR   EMDB; EMD-12174; -.
DR   EMDB; EMD-14196; -.
DR   EMDB; EMD-14197; -.
DR   EMDB; EMD-14198; -.
DR   EMDB; EMD-14199; -.
DR   EMDB; EMD-2310; -.
DR   EMDB; EMD-2311; -.
DR   EMDB; EMD-2312; -.
DR   EMDB; EMD-26086; -.
DR   EMDB; EMD-26087; -.
DR   EMDB; EMD-26088; -.
DR   EMDB; EMD-31811; -.
DR   EMDB; EMD-31812; -.
DR   SMR; O14746; -.
DR   BioGRID; 112874; 122.
DR   ComplexPortal; CPX-17; Telomerase catalytic core complex.
DR   ComplexPortal; CPX-20; TERT-RMRP complex.
DR   ComplexPortal; CPX-265; Telomerase holoenzyme complex.
DR   CORUM; O14746; -.
DR   DIP; DIP-40646N; -.
DR   ELM; O14746; -.
DR   FunCoup; O14746; 326.
DR   IntAct; O14746; 27.
DR   MINT; O14746; -.
DR   STRING; 9606.ENSP00000309572; -.
DR   BindingDB; O14746; -.
DR   ChEMBL; CHEMBL2916; -.
DR   DrugBank; DB04115; Berberine.
DR   DrugBank; DB00997; Doxorubicin.
DR   DrugBank; DB17882; Epitalon.
DR   DrugBank; DB00544; Fluorouracil.
DR   DrugBank; DB05036; Grn163l.
DR   DrugBank; DB14909; Imetelstat.
DR   DrugBank; DB04728; Lividomycin A.
DR   DrugBank; DB12747; Tertomotide.
DR   DrugBank; DB00495; Zidovudine.
DR   DrugCentral; O14746; -.
DR   GlyGen; O14746; 2 sites, 1 O-linked glycan (1 site).
DR   iPTMnet; O14746; -.
DR   PhosphoSitePlus; O14746; -.
DR   BioMuta; TERT; -.
DR   jPOST; O14746; -.
DR   MassIVE; O14746; -.
DR   PaxDb; 9606-ENSP00000309572; -.
DR   PeptideAtlas; O14746; -.
DR   ProteomicsDB; 48203; -. [O14746-1]
DR   ProteomicsDB; 48204; -. [O14746-2]
DR   ProteomicsDB; 48205; -. [O14746-3]
DR   ProteomicsDB; 73418; -.
DR   ABCD; O14746; 9 sequenced antibodies.
DR   Antibodypedia; 8998; 984 antibodies from 41 providers.
DR   DNASU; 7015; -.
DR   Ensembl; ENST00000310581.10; ENSP00000309572.5; ENSG00000164362.21. [O14746-1]
DR   Ensembl; ENST00000334602.10; ENSP00000334346.6; ENSG00000164362.21. [O14746-3]
DR   Ensembl; ENST00000460137.6; ENSP00000425003.1; ENSG00000164362.21. [O14746-4]
DR   GeneID; 7015; -.
DR   KEGG; hsa:7015; -.
DR   MANE-Select; ENST00000310581.10; ENSP00000309572.5; NM_198253.3; NP_937983.2.
DR   UCSC; uc003jcb.2; human. [O14746-1]
DR   AGR; HGNC:11730; -.
DR   CTD; 7015; -.
DR   DisGeNET; 7015; -.
DR   GeneCards; TERT; -.
DR   GeneReviews; TERT; -.
DR   HGNC; HGNC:11730; TERT.
DR   HPA; ENSG00000164362; Not detected.
DR   MalaCards; TERT; -.
DR   MIM; 187270; gene.
DR   MIM; 609135; phenotype.
DR   MIM; 613989; phenotype.
DR   MIM; 614742; phenotype.
DR   MIM; 615134; phenotype.
DR   OpenTargets; ENSG00000164362; -.
DR   Orphanet; 1501; Adrenocortical carcinoma.
DR   Orphanet; 457246; Clear cell sarcoma of kidney.
DR   Orphanet; 146; Differentiated thyroid carcinoma.
DR   Orphanet; 1775; Dyskeratosis congenita.
DR   Orphanet; 618; Familial melanoma.
DR   Orphanet; 3322; Hoyeraal-Hreidarsson syndrome.
DR   Orphanet; 88; Idiopathic aplastic anemia.
DR   Orphanet; 2032; Idiopathic pulmonary fibrosis.
DR   Orphanet; 2495; Meningioma.
DR   VEuPathDB; HostDB:ENSG00000164362; -.
DR   eggNOG; KOG1005; Eukaryota.
DR   GeneTree; ENSGT00390000018531; -.
DR   HOGENOM; CLU_001996_2_0_1; -.
DR   InParanoid; O14746; -.
DR   OMA; SYKAVQW; -.
DR   OrthoDB; 289721at2759; -.
DR   PAN-GO; O14746; 5 GO annotations based on evolutionary models.
DR   PhylomeDB; O14746; -.
DR   PathwayCommons; O14746; -.
DR   Reactome; R-HSA-171319; Telomere Extension By Telomerase.
DR   Reactome; R-HSA-201722; Formation of the beta-catenin:TCF transactivating complex.
DR   Reactome; R-HSA-9825895; Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence.
DR   SignaLink; O14746; -.
DR   SIGNOR; O14746; -.
DR   BioGRID-ORCS; 7015; 25 hits in 1168 CRISPR screens.
DR   CD-CODE; 6F24707C; Cajal body.
DR   CD-CODE; 91857CE7; Nucleolus.
DR   CD-CODE; DEE660B4; Stress granule.
DR   EvolutionaryTrace; O14746; -.
DR   GeneWiki; Telomerase_reverse_transcriptase; -.
DR   GenomeRNAi; 7015; -.
DR   Pharos; O14746; Tchem.
DR   PRO; PR:O14746; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; O14746; protein.
DR   Bgee; ENSG00000164362; Expressed in stromal cell of endometrium and 90 other cell types or tissues.
DR   ExpressionAtlas; O14746; baseline and differential.
DR   GO; GO:0000781; C:chromosome, telomeric region; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0042645; C:mitochondrial nucleoid; IDA:BHF-UCL.
DR   GO; GO:0016607; C:nuclear speck; IDA:HPA.
DR   GO; GO:0000783; C:nuclear telomere cap complex; IC:BHF-UCL.
DR   GO; GO:0005730; C:nucleolus; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IEA:Ensembl.
DR   GO; GO:0016605; C:PML body; IEA:UniProtKB-SubCell.
DR   GO; GO:0031379; C:RNA-directed RNA polymerase complex; IPI:BHF-UCL.
DR   GO; GO:0000333; C:telomerase catalytic core complex; IDA:BHF-UCL.
DR   GO; GO:0005697; C:telomerase holoenzyme complex; IDA:UniProtKB.
DR   GO; GO:1990572; C:TERT-RMRP complex; IDA:BHF-UCL.
DR   GO; GO:0003677; F:DNA binding; IDA:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:BHF-UCL.
DR   GO; GO:0051087; F:protein-folding chaperone binding; IPI:BHF-UCL.
DR   GO; GO:0003723; F:RNA binding; IPI:BHF-UCL.
DR   GO; GO:0003964; F:RNA-directed DNA polymerase activity; IDA:BHF-UCL.
DR   GO; GO:0003968; F:RNA-directed RNA polymerase activity; IDA:BHF-UCL.
DR   GO; GO:0003720; F:telomerase activity; IDA:UniProtKB.
DR   GO; GO:0070034; F:telomerase RNA binding; IDA:BHF-UCL.
DR   GO; GO:0042162; F:telomeric DNA binding; IBA:GO_Central.
DR   GO; GO:0098680; F:template-free RNA nucleotidyltransferase; IDA:BHF-UCL.
DR   GO; GO:0001223; F:transcription coactivator binding; IPI:BHF-UCL.
DR   GO; GO:0000049; F:tRNA binding; IDA:BHF-UCL.
DR   GO; GO:0071456; P:cellular response to hypoxia; IMP:BHF-UCL.
DR   GO; GO:0071897; P:DNA biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0022616; P:DNA strand elongation; IDA:BHF-UCL.
DR   GO; GO:0070200; P:establishment of protein localization to telomere; IDA:BHF-UCL.
DR   GO; GO:0007507; P:heart development; IEA:Ensembl.
DR   GO; GO:0007005; P:mitochondrion organization; IDA:BHF-UCL.
DR   GO; GO:2000773; P:negative regulation of cellular senescence; IDA:BHF-UCL.
DR   GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IEA:Ensembl.
DR   GO; GO:2001240; P:negative regulation of extrinsic apoptotic signaling pathway in absence of ligand; IMP:BHF-UCL.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IEA:Ensembl.
DR   GO; GO:0046326; P:positive regulation of D-glucose import; IEA:Ensembl.
DR   GO; GO:1900087; P:positive regulation of G1/S transition of mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0042635; P:positive regulation of hair cycle; ISS:BHF-UCL.
DR   GO; GO:1902895; P:positive regulation of miRNA transcription; IMP:BHF-UCL.
DR   GO; GO:0032092; P:positive regulation of protein binding; IDA:BHF-UCL.
DR   GO; GO:1904751; P:positive regulation of protein localization to nucleolus; IDA:BHF-UCL.
DR   GO; GO:2000648; P:positive regulation of stem cell proliferation; ISS:BHF-UCL.
DR   GO; GO:1903620; P:positive regulation of transdifferentiation; IEA:Ensembl.
DR   GO; GO:1904754; P:positive regulation of vascular associated smooth muscle cell migration; IEA:Ensembl.
DR   GO; GO:1904707; P:positive regulation of vascular associated smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0030177; P:positive regulation of Wnt signaling pathway; IGI:BHF-UCL.
DR   GO; GO:0006606; P:protein import into nucleus; IMP:DisProt.
DR   GO; GO:0031647; P:regulation of protein stability; IDA:BHF-UCL.
DR   GO; GO:0090399; P:replicative senescence; IMP:BHF-UCL.
DR   GO; GO:0046686; P:response to cadmium ion; IEA:Ensembl.
DR   GO; GO:0006278; P:RNA-templated DNA biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0001172; P:RNA-templated transcription; IDA:BHF-UCL.
DR   GO; GO:0030422; P:siRNA processing; IDA:BHF-UCL.
DR   GO; GO:0140745; P:siRNA transcription; IDA:BHF-UCL.
DR   GO; GO:0000723; P:telomere maintenance; TAS:UniProtKB.
DR   GO; GO:0000722; P:telomere maintenance via recombination; NAS:ComplexPortal.
DR   GO; GO:0007004; P:telomere maintenance via telomerase; IDA:UniProtKB.
DR   CDD; cd01648; TERT; 1.
DR   FunFam; 1.10.132.70:FF:000001; Telomerase reverse transcriptase; 1.
DR   FunFam; 1.10.357.90:FF:000001; Telomerase reverse transcriptase; 1.
DR   FunFam; 3.30.70.2630:FF:000001; Telomerase reverse transcriptase; 1.
DR   Gene3D; 1.10.132.70; -; 1.
DR   Gene3D; 1.10.357.90; -; 1.
DR   Gene3D; 3.30.70.2630; -; 1.
DR   IDEAL; IID00690; -.
DR   InterPro; IPR043502; DNA/RNA_pol_sf.
DR   InterPro; IPR000477; RT_dom.
DR   InterPro; IPR021891; Telomerase_RBD.
DR   InterPro; IPR003545; Telomerase_RT.
DR   InterPro; IPR049139; TERT_C.
DR   PANTHER; PTHR12066; TELOMERASE REVERSE TRANSCRIPTASE; 1.
DR   PANTHER; PTHR12066:SF0; TELOMERASE REVERSE TRANSCRIPTASE; 1.
DR   Pfam; PF00078; RVT_1; 1.
DR   Pfam; PF12009; Telomerase_RBD; 1.
DR   Pfam; PF21399; TERT_C; 1.
DR   PRINTS; PR01365; TELOMERASERT.
DR   SMART; SM00975; Telomerase_RBD; 1.
DR   SUPFAM; SSF56672; DNA/RNA polymerases; 1.
DR   PROSITE; PS50878; RT_POL; 1.
DR   neXtProt; NX_O14746; -.
DR   PharmGKB; PA36447; -.
DR   TreeFam; TF329048; -.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Chromosome; Cytoplasm; Disease variant;
KW   DNA-binding; Dyskeratosis congenita; Magnesium; Metal-binding;
KW   Nucleotidyltransferase; Nucleus; Phosphoprotein; Proteomics identification;
KW   Reference proteome; Ribonucleoprotein; RNA-directed DNA polymerase;
KW   Telomere; Transferase; Ubl conjugation.
FT   CHAIN           1..1132
FT                   /note="Telomerase reverse transcriptase"
FT                   /id="PRO_0000054925"
FT   DOMAIN          605..935
FT                   /note="Reverse transcriptase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00405"
FT   REGION          1..230
FT                   /note="RNA-interacting domain 1"
FT   REGION          58..197
FT                   /note="GQ motif"
FT   REGION          137..141
FT                   /note="Required for regulating specificity for telomeric
FT                   DNA and for processivity for primer elongation"
FT   REGION          210..320
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          231..324
FT                   /note="Linker"
FT   REGION          301..538
FT                   /note="Required for oligomerization"
FT   REGION          325..550
FT                   /note="RNA-interacting domain 2"
FT   REGION          376..521
FT                   /note="QFP motif"
FT   REGION          397..417
FT                   /note="CP motif"
FT   REGION          914..928
FT                   /note="Required for oligomerization"
FT   REGION          930..934
FT                   /note="Primer grip sequence"
FT   REGION          936..1132
FT                   /note="CTE"
FT   MOTIF           222..240
FT                   /note="Bipartite nuclear localization signal"
FT   MOTIF           328..333
FT                   /note="TFLY; involved in RNA binding"
FT                   /evidence="ECO:0000250|UniProtKB:Q4KTA7"
FT   COMPBIAS        213..234
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        293..304
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        310..320
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         712
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00405"
FT   BINDING         868
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00405"
FT   BINDING         869
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00405"
FT   SITE            169
FT                   /note="Required for optimal binding of telomeric ssDNA and
FT                   incorporation of nucleotides at the second position of the
FT                   template"
FT   SITE            867
FT                   /note="Required for nucleotide incorporation and primer
FT                   extension rate"
FT   MOD_RES         227
FT                   /note="Phosphoserine; by PKB/AKT1"
FT                   /evidence="ECO:0000269|PubMed:22366458"
FT   MOD_RES         457
FT                   /note="Phosphoserine; by DYRK2"
FT                   /evidence="ECO:0000269|PubMed:23362280"
FT   MOD_RES         707
FT                   /note="Phosphotyrosine; by SRC-type Tyr-kinases"
FT                   /evidence="ECO:0000269|PubMed:12808100,
FT                   ECO:0000269|PubMed:18829466"
FT   VAR_SEQ         711..722
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14654914"
FT                   /id="VSP_053369"
FT   VAR_SEQ         764..807
FT                   /note="STLTDLQPYMRQFVAHLQETSPLRDAVVIEQSSSLNEASSGLFD -> LRPV
FT                   PGDPAGLHPLHAALQPVLRRHGEQAVCGDSAGRAAPAFGG (in isoform 2 and
FT                   isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:12869302,
FT                   ECO:0000303|PubMed:14654914"
FT                   /id="VSP_019587"
FT   VAR_SEQ         808..1132
FT                   /note="Missing (in isoform 2 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:12869302,
FT                   ECO:0000303|PubMed:14654914"
FT                   /id="VSP_019588"
FT   VAR_SEQ         885..947
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14654914"
FT                   /id="VSP_021727"
FT   VARIANT         55
FT                   /note="L -> Q (in PFBMFT1; impaired telomerase activity;
FT                   dbSNP:rs387907247)"
FT                   /evidence="ECO:0000269|PubMed:17392301"
FT                   /id="VAR_062535"
FT   VARIANT         65
FT                   /note="P -> A (risk factor for acute myeloid leukemia;
FT                   dbSNP:rs544215765)"
FT                   /evidence="ECO:0000269|PubMed:19147845,
FT                   ECO:0000269|PubMed:19760749"
FT                   /id="VAR_062780"
FT   VARIANT         170
FT                   /note="V -> M (in PFBMFT1; the mutant protein is
FT                   demonstrated to cause decreased telomerase activity;
FT                   dbSNP:rs387907248)"
FT                   /evidence="ECO:0000269|PubMed:21436073"
FT                   /id="VAR_068792"
FT   VARIANT         202
FT                   /note="A -> T (in PFBMFT1 and AA; severe and moderate;
FT                   shorter telomeres; dbSNP:rs121918661)"
FT                   /evidence="ECO:0000269|PubMed:15814878,
FT                   ECO:0000269|PubMed:15885610, ECO:0000269|PubMed:19760749"
FT                   /id="VAR_036863"
FT   VARIANT         279
FT                   /note="A -> T (in dbSNP:rs61748181)"
FT                   /evidence="ECO:0000269|PubMed:15814878"
FT                   /id="VAR_036864"
FT   VARIANT         299
FT                   /note="V -> M (risk factor for acute myeloid leukemia;
FT                   dbSNP:rs756624928)"
FT                   /evidence="ECO:0000269|PubMed:19147845,
FT                   ECO:0000269|PubMed:19760749"
FT                   /id="VAR_062781"
FT   VARIANT         381
FT                   /note="R -> P (in dbSNP:rs777343359)"
FT                   /evidence="ECO:0000269|PubMed:31355908"
FT                   /id="VAR_084996"
FT   VARIANT         412
FT                   /note="H -> Y (in PFBMFT1, AA and DKCB4; severe and
FT                   moderate; risk factor for acute myelogenous leukemia; the
FT                   mutant protein has 36% residual activity;
FT                   dbSNP:rs34094720)"
FT                   /evidence="ECO:0000269|PubMed:15814878,
FT                   ECO:0000269|PubMed:18042801, ECO:0000269|PubMed:19147845,
FT                   ECO:0000269|PubMed:19760749, ECO:0000269|Ref.7"
FT                   /id="VAR_025149"
FT   VARIANT         441
FT                   /note="Missing (in AA; risk factor for acute myeloid
FT                   leukemia)"
FT                   /evidence="ECO:0000269|PubMed:15814878,
FT                   ECO:0000269|PubMed:19147845, ECO:0000269|PubMed:19760749"
FT                   /id="VAR_036865"
FT   VARIANT         522
FT                   /note="R -> K (risk factor for acute myeloid leukemia;
FT                   dbSNP:rs1751108994)"
FT                   /evidence="ECO:0000269|PubMed:19147845,
FT                   ECO:0000269|PubMed:19760749"
FT                   /id="VAR_062782"
FT   VARIANT         570
FT                   /note="K -> N (in AA; abolishes telomerase catalytic
FT                   activity but no effect on binding to TERC;
FT                   dbSNP:rs1554041299)"
FT                   /evidence="ECO:0000269|PubMed:16990594,
FT                   ECO:0000269|PubMed:19760749"
FT                   /id="VAR_062536"
FT   VARIANT         631
FT                   /note="R -> Q (in AA; dbSNP:rs199422294)"
FT                   /evidence="ECO:0000269|PubMed:19760749"
FT                   /id="VAR_062783"
FT   VARIANT         682
FT                   /note="G -> D (in AA; non-severe; abolishes telomerase
FT                   catalytic activity but little effect on binding to TERC;
FT                   dbSNP:rs199422295)"
FT                   /evidence="ECO:0000269|PubMed:16627250,
FT                   ECO:0000269|PubMed:16990594"
FT                   /id="VAR_062537"
FT   VARIANT         694
FT                   /note="V -> M (in PFBMFT1 and AA; moderate;
FT                   dbSNP:rs121918662)"
FT                   /evidence="ECO:0000269|PubMed:15814878,
FT                   ECO:0000269|PubMed:19760749"
FT                   /id="VAR_036866"
FT   VARIANT         704
FT                   /note="P -> S (in DKCB4; the mutant protein has 13%
FT                   residual activity; dbSNP:rs199422297)"
FT                   /evidence="ECO:0000269|PubMed:18042801,
FT                   ECO:0000269|PubMed:21602826"
FT                   /id="VAR_068793"
FT   VARIANT         716
FT                   /note="A -> T (in PFBMFT1; the mutant protein is
FT                   demonstrated to cause severely compromised telomerase
FT                   activity; dbSNP:rs387907249)"
FT                   /evidence="ECO:0000269|PubMed:21436073"
FT                   /id="VAR_068794"
FT   VARIANT         721
FT                   /note="P -> R (in DKCB4; no effect on telomerase catalytic
FT                   activity and little effect on binding to TERC;
FT                   dbSNP:rs199422299)"
FT                   /evidence="ECO:0000269|PubMed:16332973,
FT                   ECO:0000269|PubMed:16990594"
FT                   /id="VAR_062538"
FT   VARIANT         726
FT                   /note="T -> M (in AA; very severe; no effect on telomerase
FT                   catalytic activity but shortened telomeres;
FT                   dbSNP:rs149566858)"
FT                   /evidence="ECO:0000269|PubMed:16627250,
FT                   ECO:0000269|PubMed:16990594"
FT                   /id="VAR_062539"
FT   VARIANT         772
FT                   /note="Y -> C (in PFBMFT1; moderate; dbSNP:rs121918663)"
FT                   /evidence="ECO:0000269|PubMed:15814878"
FT                   /id="VAR_036867"
FT   VARIANT         785
FT                   /note="P -> L (in AA; dbSNP:rs483352771)"
FT                   /evidence="ECO:0000269|PubMed:19760749"
FT                   /id="VAR_062784"
FT   VARIANT         791
FT                   /note="V -> I (in PFBMFT1; associated with Met-867 in cis
FT                   on the same allele; the double mutant shows severe defects
FT                   in telomere repeat addition processivity;
FT                   dbSNP:rs141425941)"
FT                   /evidence="ECO:0000269|PubMed:21483807"
FT                   /id="VAR_068795"
FT   VARIANT         811
FT                   /note="R -> C (in DKCB4; 50% reduction in telomerase
FT                   activity; dbSNP:rs199422301)"
FT                   /evidence="ECO:0000269|PubMed:17785587"
FT                   /id="VAR_062540"
FT   VARIANT         841
FT                   /note="L -> F (in PFBMFT1)"
FT                   /evidence="ECO:0000269|PubMed:21436073"
FT                   /id="VAR_068796"
FT   VARIANT         865
FT                   /note="R -> H (in PFBMFT1; dbSNP:rs121918666)"
FT                   /evidence="ECO:0000269|PubMed:17460043"
FT                   /id="VAR_036868"
FT   VARIANT         867
FT                   /note="V -> M (in PFBMFT1; associated with Ile-791 in cis
FT                   on the same allele; the double mutant shows severe defects
FT                   in telomere repeat addition processivity; this mutation
FT                   causes most if not all of the functional defects;
FT                   dbSNP:rs201159197)"
FT                   /evidence="ECO:0000269|PubMed:21483807"
FT                   /id="VAR_068797"
FT   VARIANT         901
FT                   /note="R -> W (in DKCB4; severe phenotype overlapping with
FT                   Hoyeraal-Hreidarsson syndrome; very short telomeres and
FT                   greatly reduced telomerase activity; dbSNP:rs199422304)"
FT                   /evidence="ECO:0000269|PubMed:17785587"
FT                   /id="VAR_062541"
FT   VARIANT         902
FT                   /note="K -> N (in DKCA2; abolishes telomerase catalytic
FT                   activity but no effect on binding to TERC;
FT                   dbSNP:rs121918665)"
FT                   /evidence="ECO:0000269|PubMed:16247010,
FT                   ECO:0000269|PubMed:16990594"
FT                   /id="VAR_036869"
FT   VARIANT         902
FT                   /note="K -> R (in PFBMFT1; dbSNP:rs387907250)"
FT                   /evidence="ECO:0000269|PubMed:21436073"
FT                   /id="VAR_068798"
FT   VARIANT         923
FT                   /note="P -> L (in PFBMFT1; dbSNP:rs387907251)"
FT                   /evidence="ECO:0000269|PubMed:22512499"
FT                   /id="VAR_068799"
FT   VARIANT         948
FT                   /note="S -> R (in dbSNP:rs34062885)"
FT                   /id="VAR_053726"
FT   VARIANT         979
FT                   /note="R -> W (in DKCA2; shortened telomeres but no effect
FT                   on telomerase catalytic activity nor on binding to TERC;
FT                   dbSNP:rs199422305)"
FT                   /evidence="ECO:0000269|PubMed:15885610,
FT                   ECO:0000269|PubMed:16990594, ECO:0000269|PubMed:21602826"
FT                   /id="VAR_062542"
FT   VARIANT         1025
FT                   /note="V -> F (in PFBMFT1)"
FT                   /evidence="ECO:0000269|PubMed:21436073"
FT                   /id="VAR_068800"
FT   VARIANT         1062
FT                   /note="A -> T (increased incidence in sporadic acute
FT                   myeloid leukemia; dbSNP:rs35719940)"
FT                   /evidence="ECO:0000269|PubMed:15814878,
FT                   ECO:0000269|PubMed:19147845, ECO:0000269|PubMed:19760749,
FT                   ECO:0000269|PubMed:31355908, ECO:0000269|Ref.7"
FT                   /id="VAR_025150"
FT   VARIANT         1090
FT                   /note="V -> M (in PFBMFT1; severe; dbSNP:rs121918664)"
FT                   /evidence="ECO:0000269|PubMed:15814878"
FT                   /id="VAR_036870"
FT   VARIANT         1110
FT                   /note="T -> M (in PFBMFT1; uncertain significance; impaired
FT                   telomerase activity; dbSNP:rs199422306)"
FT                   /evidence="ECO:0000269|PubMed:17392301"
FT                   /id="VAR_062543"
FT   VARIANT         1127
FT                   /note="F -> L (in DKCA2; severe; shortened telomeres but no
FT                   effect on telomerase catalytic activity nor on binding to
FT                   TERC; dbSNP:rs1176273130)"
FT                   /evidence="ECO:0000269|PubMed:15885610,
FT                   ECO:0000269|PubMed:16990594"
FT                   /id="VAR_062544"
FT   MUTAGEN         137..141
FT                   /note="WGLLL->AAAAA: Reduced catalytic activity and repeat
FT                   addition processivity. Complete loss of catalytic activity
FT                   but no loss of binding to telomeric primers; when
FT                   associated with 930-A--A-934."
FT                   /evidence="ECO:0000269|PubMed:17296728"
FT   MUTAGEN         169
FT                   /note="Q->A: About 80% loss of enzymatic activity. Greatly
FT                   reduced incorporation of second nucleotide. Altered
FT                   strength of binding to ssDNA. Little effect on repeat
FT                   addition processivity, nor on TR interaction nor on protein
FT                   levels."
FT                   /evidence="ECO:0000269|PubMed:19777057"
FT   MUTAGEN         169
FT                   /note="Q->N: About 85% loss of enzymatic activity. Greatly
FT                   reduced incorporation of second nucleotide. Altered
FT                   strength of binding to ssDNA. No effect on protein levels
FT                   nor on TR interaction."
FT                   /evidence="ECO:0000269|PubMed:19777057"
FT   MUTAGEN         169
FT                   /note="Q->T: About 90% loss of enzymatic activity. Greatly
FT                   reduced incorporation of second nucleotide. Altered
FT                   strength of binding to ssDNA. No effect on protein levels
FT                   nor on TR interaction."
FT                   /evidence="ECO:0000269|PubMed:19777057"
FT   MUTAGEN         457
FT                   /note="S->A: Abolishes phosphorylation by DYRK2."
FT                   /evidence="ECO:0000269|PubMed:23362280"
FT   MUTAGEN         547
FT                   /note="W->A: Defective in high-affinity TERC interactions."
FT                   /evidence="ECO:0000269|PubMed:15082768"
FT   MUTAGEN         631
FT                   /note="R->A: Abolishes telomerase catalytic activity."
FT                   /evidence="ECO:0000269|PubMed:17026956"
FT   MUTAGEN         707
FT                   /note="Y->F: Abolishes oxidative stress-induced
FT                   phosphorylation and RAN binding. Impaired nuclear export
FT                   and enhanced antiapoptotic activity against ROS-dependent
FT                   apoptosis induction. Impaired interaction with PTPN11. No
FT                   dephosphorylation by PTPN11."
FT                   /evidence="ECO:0000269|PubMed:12808100,
FT                   ECO:0000269|PubMed:18829466"
FT   MUTAGEN         712
FT                   /note="D->A: Loss of telomerase activity. In the absence of
FT                   TR, no loss of binding to telomeric primers."
FT                   /evidence="ECO:0000269|PubMed:17026956,
FT                   ECO:0000269|PubMed:17296728, ECO:0000269|PubMed:9389643,
FT                   ECO:0000269|PubMed:9443919"
FT   MUTAGEN         866
FT                   /note="L->Y: Moderate reduction in telomerase activity, no
FT                   change in repeat extension rate nor on nucleotide
FT                   incorporation fidelity. Little further reduction in
FT                   activity but 13.5-fold increase in nucleotide incorporation
FT                   fidelity; when associated with M-867."
FT                   /evidence="ECO:0000269|PubMed:17264120"
FT   MUTAGEN         867
FT                   /note="V->A: About 75% reduction in telomerase activity,
FT                   about 80% reduction in repeat reduction rate and 3.9-fold
FT                   increase in nucleotide incorporation fidelity."
FT                   /evidence="ECO:0000269|PubMed:17264120"
FT   MUTAGEN         867
FT                   /note="V->M: About 75% reduction in telomerase activity,
FT                   about 50% reduction in repeat extension rate and 5.2-fold
FT                   increase in nucleotide incorporation fidelity. Little
FT                   further reduction in activity and 13.5-fold increase in
FT                   nucleotide incorporation fidelity; when associated with
FT                   Y-866."
FT                   /evidence="ECO:0000269|PubMed:17264120"
FT   MUTAGEN         867
FT                   /note="V->T: Severe reduction in telomerase activity, about
FT                   50% reduction in repeat extension rate and 2.2-fold
FT                   increase in nucleotide incorporation fidelity. No further
FT                   reduction in activity but 2.8-fold increase in nucleotide
FT                   incorporation fidelity; when associated with Y-866."
FT                   /evidence="ECO:0000269|PubMed:17264120"
FT   MUTAGEN         868..869
FT                   /note="DD->AA: Loss of telomerase activity."
FT   MUTAGEN         868
FT                   /note="D->A: Loss of telomerase activity."
FT                   /evidence="ECO:0000269|PubMed:15082768,
FT                   ECO:0000269|PubMed:15857955, ECO:0000269|PubMed:17026956,
FT                   ECO:0000269|PubMed:9389643, ECO:0000269|PubMed:9443919"
FT   MUTAGEN         869
FT                   /note="D->A: Loss of telomerase activity."
FT                   /evidence="ECO:0000269|PubMed:9389643,
FT                   ECO:0000269|PubMed:9443919"
FT   MUTAGEN         930..934
FT                   /note="WCGLL->AAAAA: Completely abolishes
FT                   telomerase-mediated primer extension and reduced binding to
FT                   short telomeric primers. Complete loss of catalytic
FT                   activity but no further loss of binding to telomeric
FT                   primers; when associated with 137-A--A-141."
FT                   /evidence="ECO:0000269|PubMed:17296728"
FT   CONFLICT        516
FT                   /note="D -> G (in Ref. 1; AAC51724)"
FT                   /evidence="ECO:0000305"
FT   HELIX           8..14
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   HELIX           15..17
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   STRAND          21..23
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   HELIX           24..31
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   STRAND          32..34
FT                   /evidence="ECO:0007829|PDB:7TRD"
FT   HELIX           45..53
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   STRAND          54..57
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   STRAND          60..62
FT                   /evidence="ECO:0007829|PDB:7TRD"
FT   HELIX           77..91
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   HELIX           96..98
FT                   /evidence="ECO:0007829|PDB:7TRE"
FT   STRAND          99..103
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   STRAND          114..123
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   HELIX           126..132
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   HELIX           135..144
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   HELIX           146..154
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   STRAND          157..162
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   TURN            163..165
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   STRAND          166..169
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   STRAND          171..173
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   TURN            175..177
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   STRAND          325..327
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   HELIX           328..331
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   STRAND          343..345
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   HELIX           346..349
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   HELIX           354..365
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   HELIX           384..387
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   HELIX           390..401
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   HELIX           405..412
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   HELIX           445..453
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   HELIX           458..472
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   HELIX           475..478
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   HELIX           481..496
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   STRAND          502..504
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   HELIX           505..508
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   STRAND          509..511
FT                   /evidence="ECO:0007829|PDB:7TRD"
FT   HELIX           518..520
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   STRAND          522..525
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   HELIX           531..550
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   HELIX           552..560
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   STRAND          561..564
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   STRAND          567..569
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   STRAND          574..577
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   HELIX           578..596
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   STRAND          598..600
FT                   /evidence="ECO:0007829|PDB:7TRD"
FT   HELIX           603..611
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   STRAND          612..614
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   STRAND          617..626
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   STRAND          629..636
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   TURN            647..649
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   STRAND          650..652
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   HELIX           654..671
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   HELIX           673..675
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   TURN            676..678
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   HELIX           683..697
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   STRAND          700..702
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   STRAND          709..713
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   TURN            714..718
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   HELIX           722..733
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   STRAND          738..749
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   STRAND          755..764
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   HELIX           766..768
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   HELIX           773..783
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   STRAND          788..796
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   HELIX           802..813
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   STRAND          815..820
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   STRAND          823..826
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   STRAND          835..837
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   HELIX           838..853
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   HELIX           855..858
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   STRAND          861..873
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   HELIX           877..889
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   TURN            892..895
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   STRAND          904..907
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   TURN            913..916
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   STRAND          919..921
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   STRAND          924..930
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   STRAND          933..936
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   TURN            937..939
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   STRAND          942..944
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   HELIX           947..949
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   STRAND          952..954
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   TURN            955..957
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   STRAND          963..965
FT                   /evidence="ECO:0007829|PDB:7TRD"
FT   HELIX           966..983
FT                   /evidence="ECO:0007829|PDB:5UGW"
FT   HELIX           984..986
FT                   /evidence="ECO:0007829|PDB:5UGW"
FT   TURN            989..991
FT                   /evidence="ECO:0007829|PDB:5UGW"
FT   HELIX           994..1017
FT                   /evidence="ECO:0007829|PDB:5UGW"
FT   HELIX           1025..1027
FT                   /evidence="ECO:0007829|PDB:5UGW"
FT   HELIX           1029..1050
FT                   /evidence="ECO:0007829|PDB:5UGW"
FT   TURN            1051..1053
FT                   /evidence="ECO:0007829|PDB:5UGW"
FT   TURN            1059..1061
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   STRAND          1062..1065
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   HELIX           1067..1082
FT                   /evidence="ECO:0007829|PDB:5UGW"
FT   HELIX           1083..1085
FT                   /evidence="ECO:0007829|PDB:5UGW"
FT   HELIX           1086..1104
FT                   /evidence="ECO:0007829|PDB:5UGW"
FT   HELIX           1111..1118
FT                   /evidence="ECO:0007829|PDB:5UGW"
FT   STRAND          1121..1123
FT                   /evidence="ECO:0007829|PDB:7QXA"
FT   TURN            1125..1129
FT                   /evidence="ECO:0007829|PDB:7QXA"
SQ   SEQUENCE   1132 AA;  126997 MW;  94E35469C4CA33A0 CRC64;
     MPRAPRCRAV RSLLRSHYRE VLPLATFVRR LGPQGWRLVQ RGDPAAFRAL VAQCLVCVPW
     DARPPPAAPS FRQVSCLKEL VARVLQRLCE RGAKNVLAFG FALLDGARGG PPEAFTTSVR
     SYLPNTVTDA LRGSGAWGLL LRRVGDDVLV HLLARCALFV LVAPSCAYQV CGPPLYQLGA
     ATQARPPPHA SGPRRRLGCE RAWNHSVREA GVPLGLPAPG ARRRGGSASR SLPLPKRPRR
     GAAPEPERTP VGQGSWAHPG RTRGPSDRGF CVVSPARPAE EATSLEGALS GTRHSHPSVG
     RQHHAGPPST SRPPRPWDTP CPPVYAETKH FLYSSGDKEQ LRPSFLLSSL RPSLTGARRL
     VETIFLGSRP WMPGTPRRLP RLPQRYWQMR PLFLELLGNH AQCPYGVLLK THCPLRAAVT
     PAAGVCAREK PQGSVAAPEE EDTDPRRLVQ LLRQHSSPWQ VYGFVRACLR RLVPPGLWGS
     RHNERRFLRN TKKFISLGKH AKLSLQELTW KMSVRDCAWL RRSPGVGCVP AAEHRLREEI
     LAKFLHWLMS VYVVELLRSF FYVTETTFQK NRLFFYRKSV WSKLQSIGIR QHLKRVQLRE
     LSEAEVRQHR EARPALLTSR LRFIPKPDGL RPIVNMDYVV GARTFRREKR AERLTSRVKA
     LFSVLNYERA RRPGLLGASV LGLDDIHRAW RTFVLRVRAQ DPPPELYFVK VDVTGAYDTI
     PQDRLTEVIA SIIKPQNTYC VRRYAVVQKA AHGHVRKAFK SHVSTLTDLQ PYMRQFVAHL
     QETSPLRDAV VIEQSSSLNE ASSGLFDVFL RFMCHHAVRI RGKSYVQCQG IPQGSILSTL
     LCSLCYGDME NKLFAGIRRD GLLLRLVDDF LLVTPHLTHA KTFLRTLVRG VPEYGCVVNL
     RKTVVNFPVE DEALGGTAFV QMPAHGLFPW CGLLLDTRTL EVQSDYSSYA RTSIRASLTF
     NRGFKAGRNM RRKLFGVLRL KCHSLFLDLQ VNSLQTVCTN IYKILLLQAY RFHACVLQLP
     FHQQVWKNPT FFLRVISDTA SLCYSILKAK NAGMSLGAKG AAGPLPSEAV QWLCHQAFLL
     KLTRHRVTYV PLLGSLRTAQ TQLSRKLPGT TLTALEAAAN PALPSDFKTI LD
//
